Literature DB >> 2259752

Extrapolation of animal toxicity to humans: interspecies comparisons in drug development.

E M Voisin1, M Ruthsatz, J M Collins, P C Hoyle.   

Abstract

Different methods for converting the dose-related toxicity of drugs from animals to humans are reviewed. Each method is analyzed with respect to its utility and limitations. Linear extrapolations from animals to humans based on body weight equivalence are shown to be inaccurate unless species-specific conversion factors are used. Extrapolations based on surface area equivalence are more accurate, do not require conversion factors, and may be used when pharmacokinetic data are not available. Ultimately, interspecies conversions are most reliable when pharmacokinetic data are available, assuming that toxic responses are comparable among species for similar blood levels. Two pharmacokinetic-based approaches may be used: direct use of plasma concentration or area under the concentration-time curve (AUC) and physiologically based pharmacokinetic (PBPK) models.

Entities:  

Mesh:

Year:  1990        PMID: 2259752     DOI: 10.1016/s0273-2300(05)80052-2

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  19 in total

1.  Research at the interface of industry, academia and regulatory science.

Authors:  William B Mattes; Elizabeth Gribble Walker; Eric Abadie; Frank D Sistare; Jacky Vonderscher; Janet Woodcock; Raymond L Woosley
Journal:  Nat Biotechnol       Date:  2010-05       Impact factor: 54.908

2.  Anti-inflammatory effects of chronic aspirin on brain arachidonic acid metabolites.

Authors:  Mireille Basselin; Epolia Ramadan; Mei Chen; Stanley I Rapoport
Journal:  Neurochem Res       Date:  2010-10-28       Impact factor: 3.996

3.  Prediction of drug clearance in humans from laboratory animals based on body surface area.

Authors:  X D Liu; J Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

4.  Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model.

Authors:  Nathan VanderVeen; Nicholas Raja; Elizabeth Yi; Henry Appelman; Philip Ng; Donna Palmer; Daniel Zamler; Marta Dzaman; Pedro R Lowenstein; Maria G Castro
Journal:  Hum Gene Ther Methods       Date:  2016-04-28       Impact factor: 2.396

Review 5.  The pharmacokinetic principles behind scaling from preclinical results to phase I protocols.

Authors:  I Mahmood; J D Balian
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

Review 6.  Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development.

Authors:  S B Charnick; R Kawai; J R Nedelman; M Lemaire; W Niederberger; H Sato
Journal:  J Pharmacokinet Biopharm       Date:  1995-04

7.  Interspecies scaling: predicting clearance of anticancer drugs in humans. A comparative study of three different approaches using body weight or body surface area.

Authors:  I Mahmood
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Jul-Sep       Impact factor: 2.441

8.  Activation of Sigma-1 Receptor Alleviates Postpartum Estrogen Withdrawal-Induced "Depression" Through Restoring Hippocampal nNOS-NO-CREB Activities in Mice.

Authors:  Suyun Zhang; Juan Hong; Tingting Zhang; Jie Wu; Ling Chen
Journal:  Mol Neurobiol       Date:  2016-03-31       Impact factor: 5.590

Review 9.  Integration of animal pharmacokinetic and pharmacodynamic data in drug safety assessment.

Authors:  D A Smith
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

10.  Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma.

Authors:  Nathan VanderVeen; Christopher Paran; Jonathan Krasinkiewicz; Lili Zhao; Donna Palmer; Shawn Hervey-Jumper; Philip Ng; Pedro R Lowenstein; Maria G Castro
Journal:  Hum Gene Ther Clin Dev       Date:  2013-09       Impact factor: 5.032

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.